90.74
前日終値:
$92.71
開ける:
$93.29
24時間の取引高:
9.60M
Relative Volume:
0.75
時価総額:
$158.05B
収益:
$45.13B
当期純損益:
$6.28B
株価収益率:
25.28
EPS:
3.5895
ネットキャッシュフロー:
$7.38B
1週間 パフォーマンス:
+0.23%
1か月 パフォーマンス:
+6.00%
6か月 パフォーマンス:
-27.58%
1年 パフォーマンス:
-33.28%
Abbott Laboratories Stock (ABT) Company Profile
名前
Abbott Laboratories
セクター
電話
(224) 667-6100
住所
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ABT
Abbott Laboratories
|
90.74 | 163.94B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
314.84 | 127.55B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
78.23 | 103.66B | 36.36B | 4.84B | 5.43B | 3.7212 |
|
BSX
Boston Scientific Corp
|
42.68 | 65.74B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
90.46 | 52.27B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-22 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 開始されました | The Benchmark Company | Buy |
| 2025-07-18 | アップグレード | Jefferies | Hold → Buy |
| 2025-06-16 | 開始されました | Leerink Partners | Market Perform |
| 2024-10-08 | 開始されました | Oppenheimer | Outperform |
| 2024-09-19 | 開始されました | Piper Sandler | Overweight |
| 2024-07-30 | ダウングレード | Edward Jones | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2023-07-21 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 繰り返されました | Barclays | Overweight |
| 2023-04-20 | 繰り返されました | Bernstein | Outperform |
| 2023-04-20 | 繰り返されました | JP Morgan | Overweight |
| 2023-04-20 | 繰り返されました | Raymond James | Outperform |
| 2023-04-20 | 繰り返されました | UBS | Buy |
| 2023-04-20 | 繰り返されました | Wolfe Research | Underperform |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2022-10-26 | 開始されました | Mizuho | Neutral |
| 2022-10-18 | 開始されました | Barclays | Overweight |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-07-06 | 開始されました | Wolfe Research | Underperform |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-01-27 | 繰り返されました | Credit Suisse | Outperform |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-01-27 | 繰り返されました | Raymond James | Outperform |
| 2022-01-27 | 繰り返されました | UBS | Buy |
| 2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-10-27 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 開始されました | Redburn | Neutral |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Neutral |
| 2021-01-28 | アップグレード | BTIG Research | Neutral → Buy |
| 2020-09-11 | 開始されました | Wolfe Research | Outperform |
| 2020-06-01 | ダウングレード | Goldman | Neutral → Sell |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2020-02-13 | 開始されました | Goldman | Neutral |
| 2020-02-06 | 再開されました | BTIG Research | Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-06-13 | 繰り返されました | BofA/Merrill | Buy |
| 2019-02-07 | 繰り返されました | BofA/Merrill | Buy |
| 2019-01-02 | ダウングレード | Citigroup | Neutral → Sell |
| 2018-11-30 | アップグレード | Goldman | Neutral → Buy |
| 2018-10-16 | 開始されました | Barclays | Overweight |
| 2018-06-27 | 開始されました | Bernstein | Outperform |
| 2018-01-30 | 繰り返されました | Citigroup | Neutral |
| 2018-01-25 | 繰り返されました | Stifel | Buy |
| 2018-01-25 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-01-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-19 | 繰り返されました | Stifel | Buy |
すべてを表示
Abbott Laboratories (ABT) 最新ニュース
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
US criminal probe into Abbott infant-formula plant closed - Global Food Industry News
Trump Admin Stopped Criminal Charges Against Abbott Nutrition for Infant Formula Illnesses - Food Safety Magazine
Abbott Laboratories earnings calendar, shares in focus on the NYSE - AD HOC NEWS
Abbott Laboratories was investigated for poisoning babies. After a $500,000 donation, Trump let them off the hook. - More Perfect Union | Substack
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo! Finance Canada
Form 4 Abbott Laboratories For: 29 June By Investing.com - Investing.com Canada
Abbott (ABT) EVP Cushman disposes 560 shares for tax withholding, retains 38,013 - Stock Titan
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Coca Cola Stock And 2 Defensive Picks For Steady Dividends - simplywall.st
MDL Sought for Abbott Spinal Cord Stimulator Lawsuits - AboutLawsuits.com
How Abbott's Largest Segment Is Preparing for the Next Growth Phase - TradingView
Abbott Laboratories dropped from Russell Top 50, shares hold above Tradegate level - AD HOC NEWS
Abbott Laboratories (ABT) Criminal Probe Closed by Justice Depar - GuruFocus
U.S. Justice Department Closes Criminal Probe into Abbott Laboratories - Intellectia AI
DOJ dropped Abbott baby formula criminal probe despite pile of evidence: WSJ (ABT:NYSE) - Seeking Alpha
US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports - Reuters
Exclusive | The Baby Formula Probe Produced a Pile of Evidence. Then the DOJ Dropped the Case. - WSJ
In a Volatile Market, This Dividend Growth Stock Is Worth Every Penny of $1,000 - The Motley Fool
Enterprise value to revenue forward of Abbott Laboratories – NYSE:ABT - TradingView
Abbott's Dual-Analyte Bet Positions It to Outpace Dexcom in the Expanding CGM Market - Kavout | AI
Abbott Laboratories (ABT) must face a Lawsuit over PediaSure, Statements about Children’s Growth - Insider Monkey
Brain Implants Market Size to Reach USD 18.39 Billion by 2035, Growing at 9.99% CAGR | SNS Insider - GlobeNewswire Inc.
Abbott Laboratories (ABT) Stock After Recent Rebound Is There Still Value Left - Yahoo Finance
Abbott Laboratories' Q2 2026 earnings: What to expect - MSN
Abbott (ABT) Expands In Europe With Instinct CGM And Emerging Market Medicines - simplywall.st
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now? - The Globe and Mail
Abbott Laboratories' Q2 2026 Earnings: What to Expect - Yahoo Finance
Abbott Laboratories sets Q2 earnings date, shares trade firmly on NYSE - Ad-hoc-news.de
Should you buy Abbott Labs stock hand over fist before July 16? - MSN
Abbott shares drop amid sector rotation but growth in diabetes and devices signals buying opportunity. - Pluang
Abbott Laboratories(NYSE: ABT) dropped from Russell Top 50 Index - marketscreener.com
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Laboratories Stock (ABT) Moved Up by 3.12% on Jun 25: A Full Analysis - TradingKey
Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy - AOL.com
Price to sales forward of Abbott Laboratories – NYSE:ABT - TradingView
Abbott Laboratories highlights diagnostics growth, shares sit in the S&P 500 health cohort - Ad-hoc-news.de
Price to sales forward of Abbott Laboratories – LSX:850103 - TradingView
$Abbott Laboratories (ABT.US)$ - Moomoo
Abbott to post Q2 results July 16, then host live webcast - Stock Titan
How An ALZpath Alzheimer’s Test Deal And Dividend Streak At Abbott (ABT) Has Changed Its Investment Story - simplywall.st
How Does Wall Street View Abbott Laboratories (ABT)’s Outlook? - Insider Monkey
ALZpath and Abbott Partner to Develop New Blood Test for Alzheimer’s Disease - Clinical Lab Products
Got $2,500? 1 Unstoppable Dividend Aristocrat With an Ironclad Moat to Buy - 24/7 Wall St.
Abbott partners with ALZpath on Alzheimer’s blood test - grafa.com
MiniMed Launches Abbott's Instinct Sensors Across European Markets - Yahoo Finance Singapore
ALZpath signs licensing deal with Abbott to develop Alzheimer's blood test - Reuters
Abbott (ABT) Partners with ALZpath for Innovative Alzheimer's Di - GuruFocus
Dividend Stocks That Could Hold Up Better If Rates Stay Higher For Longer - simplywall.st
ALZpath licenses Alzheimer’s antibody to Abbott for diagnostic test - Investing.com
ALZpath licenses Alzheimer’s antibody to Abbott for diagnostic test By Investing.com - Investing.com Canada
Abbott Laboratories (ABT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):